Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:AMPH NASDAQ:ARQT NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$20.16-3.2%$16.50$9.96▼$22.80$3.33B2.073.88 million shs2.51 million shsAMPHAmphastar Pharmaceuticals$18.88-6.0%$19.59$16.65▼$31.26$885.39M0.89534,952 shs438,665 shsARQTArcutis Biotherapeutics$28.50+3.0%$23.45$13.69▼$31.77$3.46B1.481.77 million shs1.78 million shsRAREUltragenyx Pharmaceutical$34.67-3.3%$26.31$18.29▼$42.37$3.53B0.313.07 million shs2.78 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-3.16%-2.94%+23.20%+40.30%+77.34%AMPHAmphastar Pharmaceuticals+2.40%-0.50%+1.72%-1.57%-12.16%ARQTArcutis Biotherapeutics+6.14%+5.51%+30.33%+12.43%+106.65%RAREUltragenyx Pharmaceutical+6.44%+7.43%+63.72%+54.95%-9.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$20.16-3.2%$16.50$9.96▼$22.80$3.33B2.073.88 million shs2.51 million shsAMPHAmphastar Pharmaceuticals$18.88-6.0%$19.59$16.65▼$31.26$885.39M0.89534,952 shs438,665 shsARQTArcutis Biotherapeutics$28.50+3.0%$23.45$13.69▼$31.77$3.46B1.481.77 million shs1.78 million shsRAREUltragenyx Pharmaceutical$34.67-3.3%$26.31$18.29▼$42.37$3.53B0.313.07 million shs2.78 million shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-3.16%-2.94%+23.20%+40.30%+77.34%AMPHAmphastar Pharmaceuticals+2.40%-0.50%+1.72%-1.57%-12.16%ARQTArcutis Biotherapeutics+6.14%+5.51%+30.33%+12.43%+106.65%RAREUltragenyx Pharmaceutical+6.44%+7.43%+63.72%+54.95%-9.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.57Moderate Buy$20.501.69% UpsideAMPHAmphastar Pharmaceuticals 1.63Reduce$22.0016.53% UpsideARQTArcutis Biotherapeutics 2.50Moderate Buy$34.0019.30% UpsideRAREUltragenyx Pharmaceutical 2.83Moderate Buy$58.4168.48% UpsideCurrent Analyst Ratings BreakdownLatest AMPH, RARE, ARQT, and ADPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026RAREUltragenyx Pharmaceutical Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $40.006/29/2026ADPTAdaptive Biotechnologies GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$21.00 ➝ $22.006/29/2026AMPHAmphastar Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$25.00 ➝ $20.006/24/2026ARQTArcutis Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/22/2026AMPHAmphastar Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/17/2026ADPTAdaptive Biotechnologies BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.006/3/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$23.00 ➝ $20.005/21/2026RAREUltragenyx Pharmaceutical Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$84.00 ➝ $96.005/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/12/2026ADPTAdaptive Biotechnologies Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$21.00 ➝ $18.00(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$276.98M11.65N/AN/A$1.47 per share13.71AMPHAmphastar Pharmaceuticals$719.89M1.16$4.00 per share4.72$17.17 per share1.10ARQTArcutis Biotherapeutics$376.07M9.48N/AN/A$1.55 per share18.39RAREUltragenyx Pharmaceutical$673M5.07N/AN/A($0.83) per share-41.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%8/4/2026 (Estimated)AMPHAmphastar Pharmaceuticals$98.09M$1.6611.376.443.9511.00%15.12%7.14%8/6/2026 (Estimated)ARQTArcutis Biotherapeutics-$16.14M-$0.03N/A29.69N/A-0.57%-1.41%-0.59%8/5/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)Latest AMPH, RARE, ARQT, and ADPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026ARQTArcutis Biotherapeutics$0.07N/AN/AN/A$117.54 millionN/A8/4/2026Q2 2026ADPTAdaptive Biotechnologies-$0.13N/AN/AN/A$65.81 millionN/A8/4/2026Q2 2026RAREUltragenyx Pharmaceutical-$1.25N/AN/AN/A$182.10 millionN/A5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 million5/6/2026Q1 2026ARQTArcutis Biotherapeutics-$0.02-$0.09-$0.07-$0.09$103.68 million$105.40 million5/5/2026Q1 2026ADPTAdaptive Biotechnologies-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A3.353.22AMPHAmphastar Pharmaceuticals0.793.852.82ARQTArcutis Biotherapeutics0.542.682.46RAREUltragenyx PharmaceuticalN/A2.021.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%AMPHAmphastar Pharmaceuticals65.09%ARQTArcutis BiotherapeuticsN/ARAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies5.70%AMPHAmphastar Pharmaceuticals29.60%ARQTArcutis Biotherapeutics9.40%RAREUltragenyx Pharmaceutical5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790160.04 million150.92 millionOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableARQTArcutis Biotherapeutics150125.08 million113.33 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableAMPH, RARE, ARQT, and ADPT HeadlinesRecent News About These CompaniesStock Traders Buy High Volume of Ultragenyx Pharmaceutical Put Options (NASDAQ:RARE)July 8 at 10:39 AM | marketbeat.comUltragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and SustainabilityJuly 8 at 9:30 AM | quiverquant.comQUltragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global ImpactJuly 8 at 9:08 AM | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.2% Following Analyst UpgradeJuly 7 at 1:39 PM | marketbeat.comRoyal Bank Of Canada Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) StockJuly 7 at 12:23 PM | marketbeat.com218,354 Shares in Ultragenyx Pharmaceutical Inc. $RARE Acquired by Y Intercept Hong Kong LtdJuly 6 at 6:31 AM | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Has $2.10 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RAREJuly 5 at 3:43 AM | marketbeat.comPictet Asset Management Holding SA Decreases Position in Ultragenyx Pharmaceutical Inc. $RAREJuly 3, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 8.6% - Should You Buy?June 30, 2026 | marketbeat.comUltragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?June 29, 2026 | zacks.comOP Asset Management Ltd Makes New $1.82 Million Investment in Ultragenyx Pharmaceutical Inc. $RAREJune 29, 2026 | marketbeat.comAssenagon Asset Management S.A. Purchases 2,057,951 Shares of Ultragenyx Pharmaceutical Inc. $RAREJune 26, 2026 | marketbeat.comUltragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease OpportunityJune 21, 2026 | seekingalpha.com56,238 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Flax Pond Capital LLCJune 20, 2026 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. LtdJune 20, 2026 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 19, 2026 | globenewswire.com50,000 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Ishara Investments LPJune 18, 2026 | marketbeat.comEversept Partners LP Takes $7.30 Million Position in Ultragenyx Pharmaceutical Inc. $RAREJune 18, 2026 | marketbeat.comUltragenyx Pharmaceutical Inc. $RARE Shares Sold by Catalio Capital Management LPJune 18, 2026 | marketbeat.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Rating of "Moderate Buy" by BrokeragesJune 18, 2026 | marketbeat.com683 Capital Management LLC Boosts Stock Position in Ultragenyx Pharmaceutical Inc. $RAREJune 18, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe AI Boom Has a Second Act—And It's Playing Out in OpticsBy Bridget Bennett | June 29, 2026Qualcomm Drops 25%, But Investor Day Could Reverse the SlideBy Sam Quirke | June 15, 2026USA Rare Earth Just Moved Closer to Commercial RealityBy Jeffrey Neal Johnson | June 18, 2026Energy Fuels Just Made a Bold Bet on Rare Earth MagnetsBy Jeffrey Neal Johnson | June 25, 2026Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big MovesBy Leo Miller | June 17, 2026AMPH, RARE, ARQT, and ADPT Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$20.16 -0.66 (-3.17%) Closing price 04:00 PM EasternExtended Trading$20.36 +0.20 (+0.99%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Amphastar Pharmaceuticals NASDAQ:AMPH$18.88 -1.20 (-5.98%) Closing price 04:00 PM EasternExtended Trading$18.87 -0.01 (-0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Arcutis Biotherapeutics NASDAQ:ARQT$28.50 +0.83 (+3.00%) Closing price 04:00 PM EasternExtended Trading$28.55 +0.05 (+0.18%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Ultragenyx Pharmaceutical NASDAQ:RARE$34.67 -1.20 (-3.35%) Closing price 04:00 PM EasternExtended Trading$34.66 -0.01 (-0.03%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
